FathomX: Funding, Investors & Team (Sep 2026)

FathomX is a Digital Health AI spin-off company from the National University of Singapore and National University Health System and is the brainchild of Dr Mikael Hartman (Breast Cancer Surgeon at NUH) and Dr Feng Meng Ling (Assistant Professor at the Saw Swee Hock School of Public Health). Our flagship product, FxMammo, is an AI Assistant that significantly improves the screening procedure for mammograms by reducing the false positive rates by as much as 67% and enhancing the clinical workflow by reducing the time taken to assess a screen as well as the number of radiologists required per screen. Our algorithm was based off over 3 years of research at NUS and we have recently published on the prestigious AAAI Workshop and Jama Open Network Journal. We are also a portfolio company of the MedTech JUMPStart Program. FathomX’s unique AI Model for mammogram started out in a global competition - The Dream Challenge organised by the United States’ Whitehouse. As the top Asian team in the global competition that featured more than 100 participants from around the world, the founders decided to spin-off the company with the support of NUS Enterprise. From the time of the competition, the AI model has also progressed tremendously in its predictive accuracy, refinement and users’ preference are incorporated and continuously upgraded to meet differing and progressing needs. Within a year from incorporation, the company has secured several research collaborations with major hospitals including the National University Hospital and Kandang Kerbau Women and Children’s Hospital in Singapore, Tokyo Medical and Dental University in Japan and Taipei Medical University in Taiwan. On the commercialisation front, a co-investment and co-development deal with Hewlett Packard Enterprise (HPE) was signed that will see the company gain access to HPE’s engineering team as well as potential access to over 130 hospital clients in the APAC region. We have also executed a data transfer agreement with multiple research agencies like Lifepool (Peter MacCallum Cancer Centre in Australia). The company has also recently accepted SGD1.25 Million I2Start funding Pathway and is also one of the finalists of the prestigious MedTech Innovator competition in Singapore. FathomX has also been featured on multiple news media including Channel News Asia, Tamil Seithi, Channel 8 News, Enterprise SPARKS and TEDx. We have also come up as either the champion or finalist in several competitions like the Hubei Innovate Challenge, Qingdao Innovation Challenge, IET Innovation Award Shortlist and the SHE1K C-Shark Tank' Competition.

FathomX has raised $1.6M across 2 rounds on record.

FathomX's most recent funding round on record was announced in Jun 2023. The amount was not disclosed.

FundedIQ lists Dr Mikael Hartman (Founder), Mikael Hartman (Founder) at FathomX.

FathomX is based in Singapore, Central Region, Singapore.

FathomX is in the 1-10 employee band.